key: cord-0799387-vglsv3qr
authors: Marcec, Robert; Likic, Robert
title: Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines—Much ado about nothing?
date: 2021-02-12
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14763
sha: 10e4348cc5dcb1ec31f4187b4419829f80efc899
doc_id: 799387
cord_uid: vglsv3qr

nan

fulfilled criteria for anaphylaxis. 5 The exact mechanism of PEGs' hypersensitivity remains elusive, but based on the results of basophile activation and histamine release tests, it is believed to be IgE mediated. Although it seems that hypersensitivity to PEG is rare, the possibility that it remains underrecognized and therefore underreported should be considered. 5 The American Centre for Disease Control (CDC) reported the incidence of anaphylaxis following the first dose of the Pfizer/ BioNTech vaccine to be 11.1 cases per million doses administered. It seems that postvaccination anaphylaxis is 10 times more common following the administration of the Pfizer/BioNTech vaccine than other vaccines, but it is still regarded as a rare occurrence and the CDC warns that the incidence may be overestimated as it is possible that anaphylaxis cases are reported faster than the exact number of vaccine doses administered. 6 reported as well, but it seems that the incidence is lower than that of the Pfizer/BioNTech vaccine, amounting to 2.5 cases per million Moderna doses administered, according to the CDC. 7 As it was pointed out by Polack and al., the Phase 3 BNT162b2 vaccine trial was large enough to detect with 83% probability at least one adverse event with an incidence of 0.01%, but for the detection of rarer adverse events (like anaphylaxis), it lacked sample size, as well as follow up duration. 2 Such phase 3 trial limitations in general underline the importance of phase 4 trials or post-marketing surveillance, in which the true safety profile of any drug (vaccines included) is determined. As the number of individuals receiving the vaccine increases, so too will the number of reported rare adverse events that were not detected by the phase 3 trials. Although these events are rare, they must be evaluated and properly investigated on a caseby-case basis in order to determine potential causality. The public

Oxford University/AstraZeneca COVID-19 vaccine approved

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Immunemediated adverse reactions to vaccines

Reuters. UK issues anaphylaxis warning on Pfizer vaccine after adverse reactions. Accessed: 23.1.2021. Available at

Immediate-type hypersensitivity to polyethylene glycols: a review

Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine-United States

Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine-United States

Vaccine safety: an evolving evidence-based science

Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from

COVID-19 vaccines: the importance of transparency and fact-based education